<?xml version="1.0" encoding="UTF-8"?>
<p>Baricitinib is reported to be effective in the treatment of rheumatoid arthritis in several clinical trials [
 <xref rid="B65-pharmaceuticals-13-00096" ref-type="bibr">65</xref>], with excellent results in terms of clinical response and a good safety profile [
 <xref rid="B66-pharmaceuticals-13-00096" ref-type="bibr">66</xref>]. The literature has reported that the drug blocks the phosphorylation of STATs induced by different cytokines in the blood, and it causes a transient alteration in neutrophil and lymphocyte counts [
 <xref rid="B66-pharmaceuticals-13-00096" ref-type="bibr">66</xref>,
 <xref rid="B67-pharmaceuticals-13-00096" ref-type="bibr">67</xref>,
 <xref rid="B68-pharmaceuticals-13-00096" ref-type="bibr">68</xref>,
 <xref rid="B69-pharmaceuticals-13-00096" ref-type="bibr">69</xref>].
</p>
